Top Markets
Coin of the day
Sigilon Therapeutics, Inc. Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc.

SGTX
Peringkat dalam Saham #25425
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015,... Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
Harga Saham
$22.47
Terakhir disinkronkan: 2023-08-18
Kapitalisasi Pasar
$49.76M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Sigilon Therapeutics, Inc. (SGTX)

Kategori

Riwayat harga saham Sigilon Therapeutics, Inc. (SGTX)
Harga penutupan tertinggi: $22.30 pada 2023-08-01

Harga penutupan terendah: $453.71 pada 2020-12-01
Riwayat harga saham Sigilon Therapeutics, Inc. dari 2020 hingga 2026
Performa harga saham tahunan
Tahun Performa
2023 400.06%
2022 -87.99%
2021 -91.82%
2020 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$539.14 35.65%
US
$1.04K 56.21%
NL
$117.82 -18.84%
AU
$761.87 8.65%
CH
$130.43 397.46%
US